“The only thing I will say is that we have a very competitive profile,” CEO Pascal Soriot told journalists. (iStock / Getty Images Plus) AstraZeneca is taking its oral GLP-1 drug into phase 3 on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results